Reports of a potential acquisition of U.S. rival Bristol Myers Squibb by the UK-based pharmaceutical giant AstraZeneca were met with significant market disapproval, with the company's shares dropping 9% before recovering slightly when talks were denied. This proposed deal brings to the fore long-standing challenges that British companies encounter when attempting to establish a significant presence in the United States.
The AstraZeneca situation, though the specific merger talks were reportedly not ongoing, serves as a case study in the complexities of cross-border business operations. AstraZeneca itself is a product of a 1999 merger between Sweden's Astra and the UK's Zeneca, demonstrating its own history of international integration. While the company has seen success in developing new drugs, particularly in oncology, and briefly became the most valuable firm listed in London this year, a large-scale U.S. acquisition would represent a substantial disruption to its strategy of organic growth.
Historical attempts by major UK entities to conquer the U.S. market have yielded mixed results. HSBC, now a prominent FTSE 100 company, acquired Marine Midland Bank in the 1980s to build an American banking arm. Despite becoming the 13th largest bank in the U.S. at one point, its retail operations were eventually scaled back, focusing instead on wealth management for high-net-worth clients.
Retail giants have also faced significant hurdles. Tesco, once among the world's largest retailers, invested nearly $2 billion in its failed U.S. convenience store venture, Fresh & Easy. Other UK retailers like Sainsbury's and Marks & Spencer have also struggled, though M&S has found some success selling apparel through partnerships.
Conversely, some British companies have achieved substantial success in the U.S. BAE Systems has become a major U.S. defense contractor, ranking among the top firms in that sector. Additionally, a number of businesses perceived as American are, in fact, UK-headquartered, such as the group operating InterContinental Hotels and Holiday Inn.
The broader implications extend to national strategic independence, particularly in critical sectors. The COVID-19 pandemic highlighted the importance of domestic drug production when vaccine supplies were restricted. Similarly, discussions around energy security and food security underscore the value of maintaining domestic industries. Supporting companies like AstraZeneca in their practical, on-the-ground operations within the UK is therefore viewed as a matter of common sense for bolstering national capabilities.